Email Correspondence

Showing 106 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

Swedish Logistic Property: Is the Market Overlooking a Hidden Gem?

Following recent share price movements, investors are scrutinizing Swedish Logistic Property's (OM:SLP B) valuation. With a strong long-term return profile but mixed recent financials, the key question is whether the current price accurately reflects the company's prospects in the Nordic logistics real estate sector.

Business

The Hidden Tax of Sales Tech: Why Feature Adoption Isn't ROI

A new report reveals a staggering 67% of purchased sales software features go unused, spotlighting a critical disconnect between tech spending and revenue impact. As IT budgets swell, C-suite leaders are urged to shift from measuring adoption to calculating true dollar-for-dollar returns.